Table 2. Medication.
| Variables | Fibrinolysis (N = 160) | Primary PCI (N = 1000) | No reperfusion (N = 1922) | P value |
|---|---|---|---|---|
| In-hospital | ||||
| Aspirin | 151 (94.4%) | 982 (98.2%) | 1770 (92.1%) | <0.001 |
| ADP inhibitor | 150 (93.8%) | 981 (98.1%) | 1775 (92.4%) | <0.001 |
| GP IIb/IIIa inhibitor | 11 (6.9%) | 469 (46.9%) | 186 (9.7%) | <0.001 |
| Anticoagualtion drug | 152 (95.0%) | 951 (95.1%) | 1868 (97.2%) | 0.014 |
| LWMH | 147 (91.9%) | 877 (87.7%) | 1800 (93.7%) | <0.001 |
| Fondaparinux | 5 (3.1%) | 74 (7.4%) | 68 (3.5%) | <0.001 |
| Statin | 154 (96.3%) | 980 (98.0%) | 1826 (95.0%) | <0.001 |
| β-blocker | 90 (56.3%) | 669 (66.9%) | 1087 (56.6%) | <0.001 |
| ACEI/ARB | 88 (55.0%) | 584 (58.4%) | 986 (51.3%) | 0.001 |
| Nitrate | 123 (76.9%) | 584 (58.4%) | 1472 (76.6%) | <0.001 |
| At discharge | ||||
| Aspirin | 143 (89.4%) | 904 (90.4%) | 1635 (85.1%) | <0.001 |
| ADP inhibitor | 138 (86.3%) | 896 (89.6%) | 1592 (82.8%) | <0.001 |
| Statin | 144 (90.0%) | 902 (90.2%) | 1668 (86.8%) | 0.018 |
| β-blocker | 107 (66.9%) | 634 (63.4%) | 1147 (59.7%) | 0.047 |
| ACEI/ARB | 78 (48.8%) | 468 (46.8%) | 762 (39.6%) | <0.001 |
| Nitrate | 114 (71.3%) | 471 (47.1%) | 1207 (62.8%) | <0.001 |
ADP, Adenosine diphosphate; GP Glyco-protein; LWMH, low weight molecule heparin; ACEI/ARB, angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker